Clinical trials
Moderate to Severe Atopic Dermatitis clinical trials
Below are recruiting moderate to severe atopic dermatitis clinical trials, each written for real people, not researchers. We’re tracking 97 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07370909RecruitingPhase 3
Oral LW402 for moderate-to-severe eczema
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
BeijingAges 18–75 - NCT06931990RecruitingPhase 1/Phase 2
Testing a new tablet for eczema in Chinese adults
This trial tests an experimental tablet (LT-002-158) for adults with moderate-to-severe eczema that hasn't improved enough with standard creams. The goal is to see if the tablet is safe and helps control symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07604324RecruitingPhase 1
New Drug for Moderate to Severe Eczema Treatment
This study tests a new investigational drug called DCY636 to see if it can help people with moderate to severe atopic dermatitis (eczema) that hasn't improved with topical creams. The trial starts with safety testing in healthy volunteers, then moves to people with active eczema.
FukuokaAges 18–55 - NCT06947993RecruitingPhase 2
Study of a new treatment for moderate to severe eczema
This study tests an experimental treatment for people with moderate to severe eczema that has lasted at least a year. It aims to see if the new medicine can help control symptoms better than current options.
Birmingham, AlabamaAges 18–100 - NCT06807281RecruitingPhase 3
Abrocitinib for children with eczema: long-term study
This study tests the long-term safety and effectiveness of abrocitinib (Cibinqo) for children aged 6 to 12 with moderate to severe eczema that hasn't improved with creams. It may help their skin clear and reduce itching.
Birmingham, AlabamaAges 2–11 - NCT07660835RecruitingPhase 2
A study of nemolizumab for babies with eczema
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
San Antonio, TexasAges 6 months–1.9 years - NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT07037901RecruitingPhase 2
Testing IMG-007 for moderate-to-severe eczema
This study tests a new medicine called IMG-007 for adults with moderate-to-severe eczema (atopic dermatitis) that hasn't gotten better with standard creams. The goal is to see if it safely reduces itching and skin symptoms.
Lancaster, CaliforniaAges 18–74 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT06461897RecruitingPhase 3
Comparing upadacitinib to dupilumab for eczema in children
This study tests whether an oral medicine (upadacitinib) works as well as a shot (dupilumab) for children aged 2 to 12 with moderate to severe eczema. It aims to see which treatment better controls symptoms like itching and skin rashes.
Little Rock, ArkansasAges 2–11 - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT06723080RecruitingPhase 3
Oral VC005 for moderate to severe eczema
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Nanjing, JiangsuAges 18–75 - NCT03057860Recruiting
Registry study for moderate to severe atopic dermatitis in Germany
This study is a national registry that collects information from people with moderate-to-severe atopic dermatitis (eczema). It helps doctors understand what treatments are used and how patients are doing over time.
Hanover, Lower SaxonyAges Any age - NCT07693738RecruitingPhase 1
SSGJ-716 for healthy adults and people with atopic dermatitis
This trial tests a new medicine, SSGJ-716, in healthy adults and in people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and how the body reacts to it.
ShanghaiAges 18–45 - NCT07558668RecruitingPhase 1
Testing SYX-5219 for atopic dermatitis in healthy people and patients
This trial tests a new drug called SYX-5219 to see if it is safe and how the body handles it. Part 1 and 2 use healthy volunteers, while Part 3 tests it in people with moderate to severe atopic dermatitis (eczema). The goal is to understand if this drug might help treat eczema symptoms like itching and skin inflammation.
Arkansas City, ArkansasAges 18–65 - NCT07309055RecruitingPhase 3
Study of SHR-1819 injection for teens with severe eczema
This trial tests an injectable medicine called SHR-1819 for teenagers aged 12 to 17 with severe atopic dermatitis (eczema) that has not responded well to creams or other treatments. The goal is to see if it can improve skin symptoms and reduce itching.
Shenyang, LiaoningAges 12–17 - NCT06239311RecruitingPhase 3
Methotrexate vs placebo for adults with eczema
This trial tests if methotrexate, a medication that calms the immune system, can help adults with moderate-to-severe eczema that hasn't improved with creams or other treatments. You'll either receive methotrexate or a placebo to see which works better.
Prague, Praha 1Ages 18 years+ - NCT07690371RecruitingPhase 3
Study of rezpegaldesleukin for moderate to severe eczema
This study tests an experimental medicine (rezpegaldesleukin) for people with moderate to severe eczema. It aims to see if the drug can calm the immune system and improve skin symptoms when other treatments haven't worked.
Fountain Valley, CaliforniaAges 12 years+ - NCT07211542RecruitingPhase 2
Study of SHR-1905 for moderate-to-severe eczema
This trial tests a new drug called SHR-1905 for people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and helps improve symptoms.
Guangzhou, GuangdongAges 18–75 - NCT07711418RecruitingPhase 3
A study of rezpegaldesleukin for teenagers and adults with moderate-to-severe eczema
This trial tests an investigational drug called rezpegaldesleukin for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The goal is to see if it can safely reduce eczema symptoms.
The Bronx, New YorkAges 12 years+ - NCT07746427Recruiting
Mindfulness meditation for teens with eczema
This study tests whether a smartphone-based mindfulness meditation program can help teenagers with moderate to severe eczema (atopic dermatitis) that hasn't improved with standard creams. Participants will learn relaxation techniques to possibly reduce itching and skin inflammation.
New York, New YorkAges 12–17 - NCT07298395RecruitingPhase 2
Study of ENV-294 for moderate-to-severe eczema
This trial tests an experimental cream or pill called ENV-294 in adults whose eczema is moderate to severe and hasn't gotten better with standard creams. It aims to see if ENV-294 can help control symptoms like itching and skin redness.
Birmingham, AlabamaAges 18–75 - NCT07734415Enrolling by invitationPhase 2
Long-term safety of IMG-007 for moderate-to-severe eczema
This study checks the long-term safety and effectiveness of IMG-007 in people with moderate-to-severe atopic dermatitis (eczema) who have already finished a previous IMG-007 trial.
Lancaster, CaliforniaAges 18–75 - NCT07730788Recruiting
Skin imaging study in eczema patients receiving nemolizumab
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
Romans-sur-Isère, DrômeAges 18 years+
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderate to severe atopic dermatitis?
- Yes. Clin2 currently lists 97 recruiting moderate to severe atopic dermatitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderate to severe atopic dermatitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderate to severe atopic dermatitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.